TAPO in first-line osimertinib therapy and continuation of osimertinib

Mimura, C; Kaneshiro, K; Fujimoto, S; Dokuni, R; Iwamoto, N; Matsumura, K; Hatakeyama, Y; Kono, Y; Tachihara, M

Tachihara, M (通讯作者),Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med, 7 5 1 Kusunoki cho, Chuo ku, Kobe, Hyogo 6500017, Japan.

THORACIC CANCER, 2023; 14 (6): 584

Abstract

Background: Osimertinib is associated with a relatively high frequency of drug-induced interstitial lung disease (D-ILD), and transient asymptomatic p......

Full Text Link